# Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

> **NCT01630564** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **PROCEDURE:** Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
- **BIOLOGICAL:** Umbilical Cord Blood-Derived Lymphocyte Therapy

## Key facts

- **NCT ID:** NCT01630564
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03-11
- **Primary completion:** 2018-05-30
- **Final completion:** 2018-05-30
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01630564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01630564, "Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01630564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*